Consumers who use GLP-1 medications for weight loss, like Ozempic, shift their purchasing habits. Users make fewer food and beverage purchases during the first three months of use and return closer to benchmark levels by the end of year one. Spend on groceries can reduce by 6% overall, though purchases of produce, meat, snacks, protein bars and yogurts increase. This is one of the findings of a new report from market information company Circana.
GLP-1 weight-loss users shift their spending on food purchases both in and out of home. At grocery retail, they are spending more on foods that support GLP-1 balance, including vegetables, eggs and nuts. Conversely, they are making fewer purchases of products they’ve been recommended to avoid, including spicy foods, fatty proteins, and beverages with added sugar.
The evolving behaviours reveal a clear connection between category growth and the health-driven preferences of these consumers, offering brands fresh opportunities to align with their goals. “A deeper understanding of GLP-1 medications and their roles in weight loss has unlocked new opportunities to enhance the food, beverage, and non-food products that support consumers’ overall well-being,” said Sally Lyons Wyatt, global executive vice president and chief advisor, Circana. “As accessibility, availability, and affordability of these medications improve, it will become critical for companies to develop strategies that support consumers on their health journeys.
By addressing the preferences of these consumers—such as an increased focus on protein, vegetables, and fruits, along with reduced consumption of sugar, carbs, and sodium—brands can align product innovation and marketing strategies with these consumers’ health goals. Additionally, categories such as high-protein, ready-to-eat meals, and portion-controlled snacks are well-positioned to meet the specific needs of weight loss medicine users, demonstrating the potential for growth in both traditional and emerging product segments.